The Flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights from In Silico and In Vivo Studies

Neurotoxicity Research

Volumn 26, Issue 4, 2014, Pages 331-350

  Singh, Sandeep Kumar ^a   Gaur, Ruchi ^a   Kumar, Akhil ^b   Fatima, Roshan ^c   Mishra, Lallan ^a   Srikrishna, Saripella ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b INDIAN INSTITUTE OF INFORMATION TECHNOLOGY   (India)

^c TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

Alzheimer s disease; A 42; Confocal imaging; Drosophila; Flavones; Molecular docking; Neuroprotection

Indexed keywords

1,4 BIS (3 HYDROXY 4 OXO 4H CHROMEN 2 YL)BENZENE; 1,7 BIS[4' (4 OXO 4H CHROM 2YL)PHENYL]PENTANE; 2 (4 HYDROXYCYCLOHEXA 1,4 DIENYL) 6, 8A DIHYDROCHROMEN 4 ONE; 2 (4' BENZYLOXYPHENYL) 3 HYDROXYCHROMEN 4 ONE; AMYLOID; AMYLOID BETA PROTEIN[1-42]; FLAVONOID; GLUTAMIC ACID; LYSINE; PHENYLALANINE; UNCLASSIFIED DRUG; VALINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; IMAGINAL DISC; IN VIVO STUDY; INTESTINE ABSORPTION; LARVA; LIFESPAN; MOLECULAR DOCKING; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN AGGREGATION; SCANNING ELECTRON MICROSCOPY; TRANSGENIC DROSOPHILA; ANIMAL; CAPILLARY PERMEABILITY; CHEMISTRY; COMPOUND EYE; DISEASE MODEL; DOSE RESPONSE; DROSOPHILA; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PLAQUE, AMYLOID; SURVIVAL; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; COMPOUND EYE, ARTHROPOD; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA; FLAVONOIDS; HUMANS; MOLECULAR DOCKING SIMULATION; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; SURVIVAL ANALYSIS;

EID: 84919399581     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-014-9466-z     Document Type: Article

References (75)

1. Bahia PK, Rattray M, Williams RJ (2008) Dietary flavonoid (−)epicatechin stimulates phosphatidylinositol 3-kinase-dependent anti-oxidant response element activity and up-regulates glutathione in cortical astrocytes. J Neurochem 106:2194–2204. doi:10.1111/j.1471-4159.2008.05542.x
2. Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118:401–415
3. Cabrera M, Simoens M, Falchi G et al (2007) Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure–activity relationships. Bioorg Med Chem 15:3356–3367
4. Choi Y, Kim TD, Paik SR et al (2008) Molecular simulations for anti-amyloidogenic effect of flavonoid myricetin exerted against Alzheimer’ s β -amyloid fibrils formation. Bull Korean Chem Soc 29:1505–1509
5. Commenges D, Scotet V, Renaud S et al (2000) Intake of flavonoids and risk of dementia. Eur J Epidemiol 16:357–363
6. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I (2008) Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS ONE 3:e2899. doi:10.1371/journal.pone.0002899
7. Cushnie TPT, Lamb AJ (2011) Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents 38:99–107
8. De Meyer N, Haemers A, Mishra L et al (1991) 4′-Hydroxy-3-methoxyflavones with potent antipicornavirus activity. J Med Chem 34:736–746
9. De Sousa RRR, Queiroz KCS, Souza ACS et al (2007) Phosphoprotein levels, MAPK activities and NFkappaB expression are affected by fisetin. J Enzyme Inhib Med Chem 22:439–444. doi:10.1080/14756360601162063
10. Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) Clinical trials in Alzheimer’s disease: immunotherapy approaches. J Neurochem 120 Suppl:186–193. doi:10.1111/j.1471-4159.2011.07458.x
11. Egan WJ, Lauri G (2002) Prediction of intestinal permeability. Adv Drug Deliv Rev 54:273–289. doi:10.1016/S0169-409X(02)00004-2
12. Ehrnhoefer DE, Bieschke J, Boeddrich A et al (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566. doi:10.1038/nsmb.1437
13. Esteras-Chopo A, Pastor MT, Serrano L, López de la Paz M (2008) New strategy for the generation of specific d-peptide amyloid inhibitors. J Mol Biol 377:1372–1381
14. Finelli A, Kelkar A, Song H-J et al (2004) A model for studying Alzheimer’s Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 26:365–375. doi:10.1016/j.mcn.2004.03.001
15. Frydman-Marom A, Levin A, Farfara D et al (2011) Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer’s disease animal models. PLoS ONE 6:e16564. doi:10.1371/journal.pone.0016564
16. Garg P, Verma J (2005) In silico prediction of blood brain barrier permeability: an Artificial Neural Network model. J Chem Inf Model 46:289–297. doi:10.1021/ci050303i
17. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112. doi:10.1038/nrm2101
18. Han Y-S, Zheng W-H, Bastianetto S et al (2004) Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 141:997–1005. doi:10.1038/sj.bjp.0705688
19. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185
20. Heim KE, Tagliaferro AR, Bobilya DJ (2002) Flavonoid antioxidants: chemistry, metabolism and structure–activity relationships. J Nutr Biochem 13:572–584
21. Hemming ML, Patterson M, Reske-Nielsen C et al (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 4:e262. doi:10.1371/journal.pmed.0040262
22. Hirohata M, Hasegawa K, Tsutsumi-Yasuhara S et al (2007) The anti-amyloidogenic effect is exerted against Alzheimer’s beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry 46:1888–1899. doi:10.1021/bi061540x
23. Hong YK, Park SH, Lee S et al (2011) Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer’s disease. J Ethnopharmacol 134:1028–1032
24. Hua H, Münter L, Harmeier A et al (2011) Toxicity of Alzheimer’s disease-associated Aβ peptide is ameliorated in a Drosophila model by tight control of zinc and copper availability. Biol Chem 392:919–926. doi:10.1515/BC.2011.084
25. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222. doi:10.1016/j.cell.2012.02.040
26. Inanami O, Watanabe Y, Syuto B et al (1998) Oral administration of (−)catechin protects against ischemia-reperfusion-induced neuronal death in the gerbil. Free Radic Res 29:359–365
27. Jang S, Dilger RN, Johnson RW (2010) Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr 140:1892–1898. doi:10.3945/jn.110.123273
28. Kang SS, Lee JY, Choi YK et al (2005) Neuroprotective effects of naturally occurring biflavonoids. Bioorg Med Chem Lett 15:3588–3591
29. Kayed R, Glabe CG (2006) Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol 413:326–344. doi:10.1016/S0076-6879(06)13017-7
30. Kim W, Hecht MH (2006) Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer’s Abeta42 peptide. Proc Natl Acad Sci USA 103:15824–15829. doi:10.1073/pnas.0605629103
31. Kim S-I, Jung J-W, Ahn Y-J et al (2011) Drosophila as a model system for studying lifespan and neuroprotective activities of plant-derived compounds. J Asia Pac Entomol 14:509–517
32. Landau M, Sawaya MR, Faull KF et al (2011) Towards a pharmacophore for amyloid. PLoS Biol 9:e1001080. doi:10.1371/journal.pbio.1001080
33. Larson ME, Lesné SE (2012) Soluble Aβ oligomer production and toxicity. J Neurochem 120 Suppl:125–39. doi: 10.1111/j.1471-4159.2011.07478.x
34. Lee C-W, Choi H-J, Kim H-S et al (2008) Biflavonoids isolated from Selaginella tamariscina regulate the expression of matrix metalloproteinase in human skin fibroblasts. Bioorg Med Chem 16:732–738
35. Lemkul JA, Bevan DR (2010) Destabilizing Alzheimer’s Abeta(42) protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry 49:3935–3946. doi:10.1021/bi1000855
36. Li R-S, Wang X-B, Hu X-J, Kong L-Y (2013) Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer’s disease. Bioorg Med Chem Lett 23:2636–2641
37. Lukiw WJ (2012) Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD). Expert Opin Emerg Drugs. doi: 10.1517/14728214.2012.672559
38. Luo Y, Smith JV, Paramasivam V et al (2002) Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 99:12197–12202. doi:10.1073/pnas.182425199
39. Luo W, Li Y-P, He Y et al (2011a) Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. Bioorg Med Chem 19:763–770
40. Luo W, Li Y-P, He Y et al (2011b) Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents. Eur J Med Chem 46:2609–2616
41. Manach C, Scalbert A, Morand C et al (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79:727–747
42. Mangialasche F, Solomon A, Winblad B et al (2010) Alzheimer’ s disease: clinical trials and drug development. Lancet Neurol 9:702–716. doi:10.1016/S1474-4422(10)70119-8
43. Nakagami Y, Nishimura S, Murasugi T et al (2002) A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 137:676–682. doi:10.1038/sj.bjp.0704911
44. O’Boyle NM, Banck M, James CA et al (2011) Open Babel: an open chemical toolbox. J Cheminform 3:33. doi:10.1186/1758-2946-3-33
45. Ono K, Yoshiike Y, Takashima A et al (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease. J Neurochem 87:172–181. doi:10.1046/j.1471-4159.2003.01976.x
46. Ono K, Naiki H, Yamada M (2006) The development of preventives and therapeutics for Alzheimer’s disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr Pharm Des 12:4357–4375
47. Parihar MS, Hemnani T (2004) Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci 11:456–467. doi:10.1016/j.jocn.2003.12.007
48. Petit A, Bihel F, Alvès da Costa C et al (2001) New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat Cell Biol 3:507–511. doi:10.1038/35074581
49. Pfleger CM, Wang J, Friedman L, et al. (2010) Grape-seed polyphenolic extract improves the eye phenotype in a Drosophila model of tauopathy. Int J Alzheimers Dis. doi: 10.4061/2010/576357
50. Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol 41:1261–1268. doi:10.1016/j.biocel.2008.12.015
51. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer’s disease: the cholesterol connection. Nat Neurosci 6:345–351. doi:10.1038/nn0403-345
52. Reddy GD, Pavan Kumar KNV, Duganath N, Divya RAK (2012) ADMET, Docking studies and binding energy calculations o f some Novel ACE—inhibitors for the treatment of Diabetic Nephropathy. Int J Drug Dev Res 4:268–282
53. Refsgaard HHF, Jensen BF, Brockhoff PB et al (2005) In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem 48:805–811. doi:10.1021/jm049661n
54. Reinke AA, Gestwicki JE (2007) Structure–activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 70:206–215. doi:10.1111/j.1747-0285.2007.00557.x
55. Rice-Evans CA, Miller NJ, Paganga G (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20:933–956
56. Rochet JC, Lansbury PT (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60–68
57. Scherzer-Attali R, Pellarin R, Convertino M et al (2010) Complete phenotypic recovery of an Alzheimer’s disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS ONE 5:e11101. doi:10.1371/journal.pone.0011101
58. Schroeter H, Boyd C, Spencer JPE et al (2002) MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol Aging 23:861–880
59. Selkoe DJ (1991) The molecular pathology of Alzheimer’s disease. Neuron 6:487–498
60. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
61. Sheng R, Lin X, Zhang J et al (2009) Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors. Bioorg Med Chem 17:6692–6698
62. Shin DH, Bae YC, Kim-Han JS et al (2006) Polyphenol amentoflavone affords neuroprotection against neonatal hypoxic-ischemic brain damage via multiple mechanisms. J Neurochem 96:561–572. doi:10.1111/j.1471-4159.2005.03582.x
63. Singh SK, Sinha P, Mishra L, Srikrishna S (2013) Neuroprotective role of a novel copper chelator against Aβ 42 induced neurotoxicity. Int J Alzheimers Dis 2013:567128. doi:10.1155/2013/567128
64. Sinha S, Lopes DHJ, Bitan G (2012) A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity. ACS Chem Neurosci 3:473–481. doi:10.1021/cn3000247
65. Spencer JPE, Rice-Evans C, Williams RJ (2003) Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J Biol Chem 278:34783–34793. doi:10.1074/jbc.M305063200
66. Svechkarev DA, Doroshenko AO, Kolodezny DY (2012) art%3A10.2478%2Fs11532-011-0127-2.pdf. Cent Eur J Chem 205–215
67. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615–29619. doi:10.1074/jbc.R800019200
68. Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49:3315–3321. doi:10.1021/jm051197e
69. Tjernberg LO (1999) A Molecular model of Alzheimer amyloid beta -peptide fibril formation. J Biol Chem 274:12619–12625. doi:10.1074/jbc.274.18.12619
70. Wang CN, Chi CW, Lin YL et al (2001) The neuroprotective effects of phytoestrogens on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons. J Biol Chem 276:5287–5295. doi:10.1074/jbc.M006406200
71. Williams RJ, Spencer JPE (2012) Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med 52:35–45
72. Wolff T (2011) Preparation of Drosophila eye specimens for scanning electron microscopy. Cold Spring Harb Protoc 2011:1383–1385. doi:10.1101/pdb.prot066506
73. Yang F, Lim GP, Begum AN et al (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892–5901. doi:10.1074/jbc.M404751200
74. Yen T-L, Hsu C-K, Lu W-J et al (2012) Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), in ischemic stroke of rats. J Agric Food Chem 60:1937–1944. doi:10.1021/jf204909p
75. Zhang H, Ma Q, Zhang Y, Xu H (2012) Proteolytic processing of Alzheimer’s β-amyloid precursor protein. J Neurochem 120 Suppl:9–21. doi:10.1111/j.1471-4159.2011.07519.x